The value of platelet inhibitors in the secondary prophylaxis of stroke - A review;Stellenwert von thrombozyten-aggregationshemmern in der sekundarprävention des ischämischen schlaganfalls

Fortschritte der Neurologie Psychiatrie

Volumn 72, Issue 5, 2004, Pages 270-281

  Schellinger, Peter D ^a   Juttler E ^a   Meyding Lamadé, Uta K ^a   Schwark, C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HEPARIN; LAMIFIBAN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; ORTOFIBAN; PRAVASTATIN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

BRAIN ISCHEMIA; BRAIN PROTECTION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DIABETES MELLITUS; DIARRHEA; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG USE; DYSPEPSIA; HEART INFARCTION; HEART SURGERY; HIGH RISK POPULATION; HUMAN; INFORMED CONSENT; MEDICAL LITERATURE; META ANALYSIS; NAUSEA; NEUTROPENIA; ORGANIZATION; PRACTICE GUIDELINE; PUBLICATION; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; BRAIN ISCHEMIA; CLINICAL TRIALS; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 2542470450     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-812448     Document Type: Review

References (101)

1. Wolf PA, Cobb JL, D'Agostino RB. Epidemiology of stroke. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM (eds.). Stroke: Pathophysiology, diagnosis and management. New York: Churchill Livingston, 1992: 3-27
2. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of tia. Jama 2000; 284: 2901-2906
3. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC. Risk factors, outcome, and treatment in subtypes of ischemic stroke: The german stroke data bank. Stroke 2001; 32: 2559-2566
4. Diener HC. Stroke prevention - antiplatelet and antithrombolytic therapy. Neurologic Clinics 2000; 19: 343-355
5. Antiplatelet Trialists's Collaboration. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation - collaborative overview of randomised trials of antiplatelet therapy - i: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Stroke prevention in atrial fibrillation ii study. Nouv Rev Fr Hematol 1994; 36: 213-228
6. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj 2002; 324: 71-86
7. Diener HC, Hacke W. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag, 2002
8. Hacke W. From cure to match: Adp receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002; 13 Suppl 1: 22-26
9. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, Garber S, McCaffrey DF, Dake MD, Levin RA. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33: 901-906
10. Diener HC. Sekundärprävention zerebraler Durchblutungsstö rungen. In: Hartmann A, Heiss WD (eds.). Der Schlaganfall - Pathogenese, Klinik, Diagnostik und Therapie akuter zerebrovaskulärer Erkrankungen. Darmstadt: Steinkopff, 2001: 463-476
11. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119: 300S-320S
12. The European Stroke Initiative. Recommendations for stroke management. Cerebrovasc Dis 2000; 10: 1-34
13. Hart RG, Palacio A, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy-analysis of randomized clinical trials. Stroke 2002; 33: 2722-2727
14. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, Nasco E. Cardioembolic vs. Noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000; 10: 39-43
15. The European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262
16. The European Atrial Fibrillation Trial (EAFT) Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10
17. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 2003; 138: 831-838
18. The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-865
19. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, Pessin MS, Weichel E, Sila CA, Furlan AJ et al. The warfarin-aspirin symptomatic intracranial disease study. Neurology 1995; 45: 1488-1493
20. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams Jr HP, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-1451
21. Esprit. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. Stroke 2003; 34: E45-46
22. Benesch CG, Chimowitz MI. Best treatment for intracranial arterial stenosis? 50 years of uncertainty. The wasid investigators. Neurology 2000; 55: 465-466
23. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest 2001; 119: 22S-38S
24. Schellinger P, Orberk E, Hacke W. Antithrombotic therapy following cerebral ischaemia. Fortschr Neurol Psychiat 1997; 65: 425-434
25. Lee KY, Heo JH, Lee SI, Yoon PH. Rescue treatment with abciximab in acute ischemic stroke. Neurology 2001; 56: 1585-1587
26. Junghans U, Seitz RJ, Wittsack HJ, Aulich A, Siebler M. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein iib/iiia inhibitor: Report of four cases. Radiology 2001; 221: 795-801
27. Junghans U, Seitz RJ, Ritzl A, Wittsack HJ, Fink GR, Freund HJ, Siebler M. Ischemic brain tissue salvaged from infarction by the gp iib/iiia platelet antagonist tirofiban. Neurology 2002; 58: 474-476
28. Memon MA, Blankenship JC, Wood GC, Frey CM, Menapace FJ. Incidence of intracranial hemorrhage complicating treatment with glycoprotein iib/iiia receptor inhibitors: A pooled analysis of major clinical trials. Am J Med 2000; 109: 213-217
29. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet 2000; 355: 337-345
30. Topol EJ, Easton JD, Amarenco P, Califf R, Harrington R, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Shuaib A, Koudstaal PJ, Theroux P, Werf F van de, Willerson JT, Chan R, Samuels R, Ilson B, Granett J. Design of the blockade of the glycoprotein iib/iiia receptor to avoid vascular occlusion (bravo) trial. Am Heart J 2000; 139: 927-933
31. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Val Med J 1956; 78: 213-215
32. Schrör K. Antiplatelet drugs. Drugs 1995; 50: 7-28
33. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. Bmj 2000; 321: 1183-1187
34. Rajagopalan S et al. The stimulation of arachidonic acid metabolism in human platelets by hydrodynamic stress. Biochem Biophys Acta 1988; 958: 108-115
35. Chinese Acute Stroke Trial Collaborative Group. Cast: Randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649
36. International Stroke Trial Collaborative Group. The international stroke trial (ist): A randomised trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581
37. Algra A, Gijn J van. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66: 255
38. The SALT Collaborative Group. Swedish aspirin low-dose trial (salt) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-1349
39. The UK-TIA Study Group. The united kingdom transient ischaemic attack (uk-tia) aspirin trial: Final results. J Neurol Neurosurg Psychiatr 1991; 54: 1044-1054
40. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13
41. Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? Stroke 1996; 27: 756-760
42. Algra A, Gijn J van. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996; 60: 197-199
43. Buchanan MR, Brister SJ. Individual variation in the effects of asa on platelet function: Implications for the use of asa clinically. Can J Cardiol 1995; 11: 221-227
44. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235
45. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266
46. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218-2224
47. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial. Asa and carotid endarteractomy (ace) trial collaborators. Lancet 1999; 353: 2179-2184
48. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: Final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register 1998; 63: 56802-56819, 66015-66017
49. Rotondo S et al. Ticlopidine does not reduce in vivo platelet thromboxane biosynthesis and metabolism in diabetic patients. Platelets 1993; 56: 147-150
50. Pengo V et al. Adenosine diphosphate (adp) induced alpha-granules release from platelets of native whole blood. Is reduced by ticlopidine but not by aspirine or dypiramidole. Thromb Haemost 1986; 4: 97-100
51. Hardisty RM et al. The action of ticlopidine on human platelets: Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990; 64: 150-155
52. Ono S et al. Hemorrhagical effect of ticlopidine in the rat. Thromb Res 1983; 31: 549-556
53. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American ticlopidine study (cats) in thromboembolic stroke. Lancet 1989; 1: 1215-1220
54. Hass WK, Easton JD, Adams Jr HP, Pryse Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine aspirin stroke study group. N Engl J Med 1989; 321: 501-507
55. Murray JC, Kelly MA, Gorelick PB. Ticlopidine: A new antiplatelet agent for the secondary prevention of stroke. Stroke 1994; 25: 2337-2342
56. Chen DK, Kim JS, Sutton DM. Thrombotic thrombocytopenic purpura associated with ticlopidine use: A report of 3 cases and review of the literature. Arch Intern Med 1999; 159: 311-314
57. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128: 541-544
58. Weisberg LA. The efficacy and saftey of ticlopidine and aspirin in non-whites. Neurology 1993; 43: 27-31
59. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. Jama 2003; 289: 2947-2957
60. Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, Schomig A. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997; 29: 1515-1519
61. Leon MB, Popma JJ, Mintz GS, Pichard AD, Satler LF, Kent KM. An overview of us coronary stent trials. Semin Interv Cardiol 1996; 1: 247-254
62. Savi P, Bernat A, Dumas A, Ait Chek L, Herbert JM. Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. Thromb Res 1994; 73: 117-124
63. Herbert JM, Frehel D, Vallee E et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198
64. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-2286
65. CAPRIE Steering Committee. A randomized trial of clopidogrel vs aspirin in patients at risk of ischemic events. Lancet 1996; 348: 1329-1339
66. Moloney BA. An analysis of the side-effects of ticlopidine. In: Hass WK, Easton JD (eds.). Ticlopidine, platelets and vascular disease. New York: Springer-Verlag New York Inc, 1993: 117-139
67. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-1777
68. Wie viel Fortschritt kostet: Beispiel Clopidogrel. Cardio News 2003; 5 (6): 16
69. Hankey GJ. Stroke: How large a public health problem, and how can the neurologist help? Arch Neurol 1999; 56: 748-754
70. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103: 363-368
71. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Caprie investigators. Am Heart J 2000; 140: 67-73
72. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003; 107: 32-37
73. Igel M, Sudhop T, Bergmann K von. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme a-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-364
74. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: The prospective pravastatin pooling (ppp) project. Circulation 2001; 103: 387-392
75. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000; 109: 371-377
76. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli I, Oto A, White C, Webb-Peploe M, Belle E van, McFadden EP. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98: 1597-1603
77. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80: 512-518
78. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823-2828
79. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36: 699-705
80. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, Ellis SG, Topol EJ. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14
81. Bertrand M. The classics-study: Clopidogrel aspirin stent international cooperative study. American College of Cardiology, 48th Annual Scientific Session. 1999
82. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101: 590-593
83. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104: 539-543
84. Mehta SR, Yusuf S. The clopidogrel in unstable angina to prevent recurrent events (cure) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21: 2033-2041
85. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 2001; 345: 494-502
86. Steinhubl SR, Berger PB, Mann 3rd JT, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. Jama 2002; 288: 2411-2420
87. Easton JD. Evidence with antiplatelet therapy and adp-receptor antagonists. Cerebrovasc Dis 2003; 16 Suppl 1: 20-26
88. Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harker LA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 1998; 114: 470S-488S
89. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: Modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12-18
90. Strauer BE, Heidland UE, Vogt M, Schwartzkopff B, Heintzen MP. Protection and "preconditioning" of the human heart during percutaneous transluminal coronary angioplasty (ptca) by intracoronary dipyridamole administration. Med-Klin 1995; 90: 125-130
91. Kirchmaier CM, Altorjay J, Bellinger O, Breddin HK. Inhibition of induced thrombocyte aggregation in the presence of endothelial cells by dipyridamole. Vasa Suppl 1991; 32: 318-321
92. Wilterdink JL, Easton JD. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999; 56: 1087-1092
93. The ESPS Group. The european stroke prevention study (esps). Principal end-points. Lancet 1987; 2: 1351-1354
94. Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M. Cardiac safety in the european stroke prevention study 2 (esps2). Int J Clin Pract 2001; 55: 162-163
95. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338.191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004: 75 (1): 40-47
96. Rosendaal FR, Algra A. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1997; 150: 85-87
97. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-i: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Bmj 1994; 308: 81-106
98. The American-Canadian Co-Operative Study group. Persantine aspirin trial in cerebral ischemia. Part ii: Endpoint results. Stroke 1985; 16: 406-415
99. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, Touboul PJ. "aicla" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5-14
100. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. [prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]. Rev Neurol (Paris) 1982; 138: 367-385
101. Yusuf S. From the hope to the ontarget and the transcend studies: Challenges in improving prognosis. Am J Cardiol 2002; 89: 18A-25A; discussion 25A-26A